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Abstract
Objective. Diagnosis of coeliac disease is based on the presence of villous atrophy which recovers following a gluten-free
diet. The presence of circulating antiendomysial antibodies as well as their disappearance after a gluten-free diet supports
the diagnosis. It has also been demonstrated that antiendomysial antibodies are detectable in supernatants of cultured
intestinal biopsies from patients with coeliac disease. The objective of this study was to compare the histology and
antiendomysial antibodies in culture supernatants of intestinal biopsies to validate the in vitro organ culture system as a
future diagnostic tool for coeliac disease. Material and methods. Seventy-five antiendomysial serum-positive patients on
a gluten-containing diet were evaluated. Patients underwent endoscopy with 5 biopsy fragments: 3 for histology, 1 cultured
with and the other without gliadin-peptide activator. Antiendomysial antibodies were evaluated in all culture super-
natants. Results. Sixty-eight patients had evidence of villous atrophy, while 73 out of 75 were positive to the organ culture
system. The agreement rate between organ culture and histology results was 94%. Conclusions. As all the centres
participating in the study obtained good agreement between organ culture and histology results, the new system could be
considered a reliable tool for the diagnosis of coeliac disease. Nevertheless, it is possible to highlight cases with an organ
culture-positive and -negative histology. This feature could be of considerable interest because, as the sensitivity of organ
culture seems to be greater than the initial histology, the new system might be useful in uncertain cases where the risk of
missing the diagnosis of coeliac disease is high.
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Introduction
The diagnosis of coeliac disease (CD) is currently
based on a histological examination of the intestinal
mucosa demonstrating villous atrophy which re-
covers following a gluten-free diet (GFD) [1]. The
presence of circulating antiendomysial (EMA) and/
or anti-tissue-transglutaminase (anti-tTG) antibo-
dies and their disappearance after a GFD support
the diagnosis [2,3].
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Today, positive serum EMA and/or anti-tTG
alone are insufficient to diagnose CD. However,
the widespread use of these screening tests, espe-
cially when they are used in a way that maximizes
their sensitivity, contrasts with the limits that the
histology involves, such as technical difficulties
(i.e. correct orientation and sufficient size of the
biopsy samples) and subjective data interpretation.
Furthermore, at the routine histological examina-
tion, it is possible to highlight patchy features of
intestinal damage (specially in randomness of the
biopsy drawing condition) and, in the latent form of
CD, absence of mucosal atrophy despite the appear-
ance of villous flattening after a prolonged period of
gluten ingestion [4,5].
On the other hand, it has previously been demon-
strated that the production of EMA antibodies
occurs in the intestinal mucosa and that these
antibodies can be detected in the supernatants of
cultured intestinal biopsies from untreated CD
patients [6/8]. Subsequently, the use of other
methods (e.g. phage display libraries) has confirmed
that EMA antibodies are in fact produced in the
small intestinal mucosa [9,10]. The presence of
EMA antibodies can also be demonstrated in the
supernatants of cultured intestinal biopsies from CD
patients undergoing GFD after in vitro treatment
with antigenic stimulus (in vitro gliadin challenge)
[6]. The same results have been achieved by using a
synthetic peptide corresponding to the 31/43 AA
position of a-gliadin [11]. Even though the in vitro
gliadin challenge results reported in the literature
tend to be variable [6/8], it is today known that the
in vitro production of EMA antibodies is gluten
dependent and highly specific for CD [12,13].
In this collaborative study, the overall aim was to
compare histological findings and EMA detection in
supernatants of intestinal biopsies cultured with or
without gliadin to validate the in vitro organ culture
system (EMA biopsy) as a future diagnostic tool
for CD.
Material and methods
Patients
This multinational cooperative study involved six
centres: five (Rome, Milan, Florence, Palermo /
Italy; Buenos Aires / Argentina) dealt with adult
and one with paediatric patients (Valencia / Spain).
A total of 75 subjects (16 M, 59 F, median age 28
years, range 1/65 years) referred for diagnosis of CD
were included in the study. The inclusion criteria
consisted of symptoms suggestive of CD on a gluten-
containing diet and positive serum IgA EMA.
In each centre, symptoms and signs were collected
on specifically designed data sheets and sent to the
coordination centre (Rome) for data processing.
Fifty percent of the patients who took part in the
study presented a body mass index of less than 20.
The most frequent symptoms were: abdominal pain
(37%); muscular cramps (36%); diarrhoea (34%);
aphthosis (31%); defluvium, paresthesia and teeth
enamel hypoplasia (27%); clubbing and diskeratosis
(24%); spontaneous ecchymosis (21%). The most
frequent abnormal blood data were: hypoferritinae-
mia (40%); iron-deficiency anaemia (35%); increase
of alanine aminotransferase (ALAT) (32%) and
aspartate aminotransferase (ASAT) (26%) transami-
nase; low serum levels of cholesterol (31%) and
triglycerides (24%).
All patients in the study underwent oesophago-
gastroduodenoscopy (OGDS) in order to collect
5 biopsy fragments from the II/III duodenal part
(minimal weight required: 5 mg/fragment), 3 for
routine histological examination and 2 for organ
culture.
All procedures followed in this study, performed
for diagnostic purposes, were in agreement with the
ethics standards of the institutional committee
responsible for human experimentation.
Histology
Morphometric analysis was performed by means of
the standard haematoxylin-eosin staining technique.
The histological status was evaluated in agreement
with both original and revised Marsh classification,
and grade 3 lesions were considered diagnostic for
CD [14,15].
EMA biopsy system
Organ culture. Two duodenal specimens were cul-
tured as previously reported [12]. Briefly: specimens
were gently placed in a sterile tube containing 500 ml
of medium and then cultured for 48 h at 378C, one
along with and one without the activator (a synthetic
peptide corresponding to the 31/43 AA position of
a-gliadin) (Antiendomysium Biopsy Kit / Eurospi-
tal, Trieste, Italy). Supernatants were collected and
stored at /208C, until in use.
Antiendomysial antibody detection. EMA antibodies
were sought in culture supernatants by means of
indirect fluorescence assay (IFA) on cryostat sec-
tions of monkey oesophagus (Eurospital). Undiluted
culture supernatants were incubated for 45 min.
Fluorescein isothiocyanate (FITC)-conjugated anti-
human IgA, diluted 1:100, was incubated for 30
min. Positive results were identified by reticulin-like
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staining of smooth-muscle bundles. For each centre
participating in the study, the results were evaluated
by an observer unaware of the clinical conditions of
the studied subjects.
Results
At the histological examination, 22 out of 24 Rome
patients had evidence of villous atrophy (7 with IIIa,
4 with IIIb and 11 with grade IIIc of the Marsh
classification) while, the remaining 2 patients, had
no histological signs suggestive of CD (1 with I, and
the other one with 0 grade of the Marsh classifica-
tion). All 24 patients were positive to the EMA
biopsy system, irrespective of the in vitro gliadin
challenge.
Florence
Sixteen out of 19 patients had evidence of villous
atrophy (1 with IIIa and 15 with grade IIIb of the
Marsh classification) while, the remaining 3 patients,
had no histological signs suggestive of CD (1 with I
and the other two with 0 grade of the Marsh
classification). Seventeen patients (16 with III and
1 with grade 0 of the Marsh classification) were
positive to the EMA biopsy system, irrespective of
the in vitro gliadin challenge. Of the remaining two
patients, one (grade 0 of the Marsh classification)
was negative while the other patient (grade I of the
Marsh classification) was positive only after in vitro
gliadin challenge.
Buenos Aires
All 10 patients had evidence of villous atrophy
(1 with IIIa, 1 with IIIb and 8 with grade IIIc of
the Marsh classification). Nine patients were positive
to the EMA biopsy system, irrespective of the in vitro
gliadin challenge. The remaining patient was posi-
tive after biopsy culture with medium alone and,
conversely, negative after biopsy culture in the
presence of antigenic stimulus.
Palermo
Seven out of 8 patients had evidence of villous
atrophy (4 with IIIb and 3 with grade IIIc of the
Marsh classification), while the remaining patient
had no histological signs suggestive of CD (grade I of
the Marsh classification). All 8 patients were positive
to the EMA biopsy system, irrespective of the in vitro
gliadin challenge.
Milan
All 7 patients had evidence of villous atrophy (1 with
IIIa, 4 with IIIb and 2 with grade IIIc of the Marsh
classification). All 7 patients were positive to the
EMA biopsy system, irrespective of the in vitro
gliadin challenge.
Valencia
Six out of 7 patients had evidence of villous atrophy
(5 with IIIb and 1 with grade IIIc of the Marsh
classification) while the remaining patient had no
histological signs suggestive of CD (grade I of the
Marsh classification). Five patients (all with mucosal
atrophy) were positive to the EMA biopsy system,
irrespective of the in vitro gliadin challenge. Of the
remaining two patients, one (grade I of the Marsh
classification) was negative while the other patient
(grade IIIb of the Marsh classification) was positive
only after in vitro gliadin challenge.
All data are summarized in Table I.
Discussion
The diagnosis of CD is generally based on three
parameters: clinical case identification, screening
tests and confirmation tests. Over the past few years
the clinical presentation of the disease has been
better understood, added to which more sensitive
Table I. Centres participating in the study, the number of patients evaluated by each centre, the number of positive histologies (grades IIIa,
IIIb and IIIc of the Marsh classification), the number of positive results of the EMA biopsy system (for both specimens cultured in medium
alone and those cultured in medium plus gliadin) and the agreement rate between EMA biopsy and histology results.
EMA biopsy positive results
Centres (no. of patients) Positive histology Medium Medium/gliadin Final results Agreement rate
Rome (24) 22 24 24 24 92%
Florence (19) 16 17 18 18 89%
Buenos Aires (10) 10 10 9 10 100%
Palermo (8) 7 8 8 8 88%
Milan (7) 7 7 7 7 100%
Valencia (7) 6 5 6 6 100%
Total patients (75) 68 71 72 73 94%
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and specific diagnostic tools have been used. Not-
withstanding, these parameters are currently being
modified and upgraded.
In agreement with the last ESPGHAN criteria, if
symptoms and signs (typical and/or atypical) plus
screening tests (EMA and/or anti-tTG antibodies)
are suggestive of CD, then intestinal mucosal sam-
ples with histological features as defined by the
Marsh classification are sufficient to confirm the
diagnosis. A favourable response to the GFD is
mandatory, as well as disappearance of serum EMA
and anti-tTG antibodies [2,3]. However total villous
atrophy, identified as the gold standard for CD
diagnosis, is considered the extreme condition of a
modifying spectrum of tissue damage that can be
revealed only during the acute phase of the disease
[3]. For this reason, it is possible to highlight false-
negative results, especially in the case of patchy
atrophy (4) or in the absence of mucosal damage, a
feature readily found in latent CD [5], and conse-
quently the diagnosis could be missed. Together with
the technical difficulty (correct orientation and
sufficient size of the biopsy fragments), the subjec-
tive evaluation of the intestinal damage adds further
limitations to the diagnosis of CD when the histo-
logical analysis is the only confirmation test per-
formed. All these features indicate the need for
considering other tools in the final step of CD
diagnosis.
Given the evidence that EMA antibodies are
produced by the intestinal mucosa and are then
detectable in supernatants of biopsies from un-
treated CD patients cultured in the absence and/or
presence of antigenic stimulus (gliadin) [6/8,12,13],
we evaluated the reliability of the in vitro EMA
biopsy in diagnosing CD, in comparison with the
‘‘classic’’ histology. The data highlight that all
gastroenterology centres participating in the study
obtained a high agreement rate between EMA
biopsy and histology (from 88 to 100%, mean
agreement rate 94%), suggesting that the new
system could be useful in the diagnostic iter of CD.
Although EMA determination in serum is easier
than that in culture supernatant and, generally,
immunofluorescence requires expertise, the EMA
biopsy is an economical method that is easy to set up
in each laboratory. Since to diagnose CD, an
endoscopy with biopsies is mandatory, reserving an
intestinal fragment for EMA biopsy would offer an
additional tool that could display the EMA anti-
bodies locally where they are produced.
Moreover, in 70 out of 73 EMA biopsy positive
cases, antibodies were detectable in supernatants
irrespective of the in vitro gliadin challenge. In 2 of
the remaining 3 cases, (1 in Florence and 1 in
Valencia) EMA antibodies were detectable only after
in vitro gliadin challenge. This feature suggests that
the in vitro gliadin challenge should always be
performed when the EMA biopsy system is used in
the diagnostic protocol of CD. On the other hand, in
the last EMA biopsy positive case (Buenos Aires),
antibodies were detectable only after culture with
medium alone. This was probably due to the low
weight of the fragment cultured in the presence of
gliadin peptide (1.2 mg versus 5 mg/fragment
required), suggesting that particular attention should
be paid to the size of the intestinal samples used for
EMA biopsy tests.
In the two serum EMA-positive but EMA biopsy
negative cases (1 in Florence and 1 in Valencia), the
histology was also negative, even though both
patients presented a clinical spectrum and a series
of haematochemical data typical of CD. Further-
more, one of these patients presented a family
history of CD and the HLA DQ2 type (Table II).
A possible explanation for the EMA biopsy negative
results could be that, in these cases, biopsy speci-
mens were not adequate.
Finally, the histology was negative in 5 patients
who showed EMA biopsy positive results (2 in
Rome, 2 in Florence and 1 in Palermo). These
patients presented positive serum EMA, HLA DQ2
type, family history, symptoms and signs suggestive
of CD (Table III), but could not be given a diagnosis
because villous atrophy was not present. This feature
suggests a possible use of the EMA biopsy system to
clarify the diagnosis in cases of gluten-sensitive
enteropathy characterized by an infiltrative/hyper-
plastic histological pattern (I/II grade of the Marsh
classification) or in cases of patchy condition of the
villous atrophy.
As all the gastroenterology centres participating in
the study obtained good agreement between EMA
biopsy and histology results, the new system could
Table II. Clinical spectrum (family history, clinical presentation, HLA typing and haematochemical data) of the two patients with positive
serum EMA but EMA biopsy and histology negative results.
Patients (centre) Relatives with CD Clinical presentation HLA Haematochemical suggestive data
Pts 1 (Florence) Cousin Typical DQ2 ¡/ Haemoglobin; ¡/ ferritin; ¡/ cholesterol
Pts 2 (Valencia) / Typical / ¡/ Haemoglobin; ¡/ iron; / transaminase; ¡/ cholesterol
Abbreviations: HLA/human lymphocyte antigen; EMA/antiendomysial; CD/coeliac disease; pts/patients.
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be considered a reliable tool for the diagnosis of CD.
Nevertheless, it is possible to highlight cases,
strongly suspected to have CD, with EMA biopsy
positive results but negative histology. Consequently,
correct values of sensitivity and specificity of the
EMA biopsy system are not measurable if the choice
of the reference gold standard is based on the
histological evidence of villous atrophy. However, a
prospective study to verify gluten dependency in
patients with EMA biopsy positive results but
negative histology is foreseeable. This study should
be of considerable interest because, as the sensitivity
of EMA biopsy seems to be greater than the initial
histology, the new system could be useful for the
uncertain cases (patchy atrophy or latent CD),
where the risk of missing the diagnosis of CD is
very high.
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